Novacyt announces that, as of May 1, its Executive Director Lyn Rees will become Chief Executive Officer, replacing James McCarthy who will leave the Board of Directors, but will remain with the company for some time.

In addition, Chief Scientific Officer Joanne Mason will join Novacyt's Board of Directors as a Director as of May 1, while non-executive Director Andrew Health will retire from the Board.

In addition, Novacyt indicates that the publication of its annual results for 2023, initially scheduled for April 30, will take place by the end of May 2024, due to the delay in integrating Yourgene Health into its consolidated results.

Copyright (c) 2024 CercleFinance.com. All rights reserved.